Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Daiichi Sankyo Co Ltd to Apply for Marketing Approval for Anti-influenza Agent Inavir-Chemical Daily
Chemical Daily reported that Daiichi Sankyo Co Ltd announced that is has submitted an application to Ministry of Health, Labor and Welfare, applying for the manufacturing and marketing approval of its anti-influenza agent inavir.
Latest Developments for Daiichi Sankyo Co Ltd
- Daiichi Sankyo Co Ltd to Apply for Delisting from Nagoya Stock Exchange
- Daiichi Sankyo Co Ltd And Ranbaxy Laboratories Ltd Announce Intention To Integrate Business Operations In Thailand
- Daiichi Sankyo Co Ltd and ArQule, Inc. Announces Top-Line Results Of Phase 2 Trial With Tivantinib in Colorectal Cancer
- Arqule Inc And Daiichi Sankyo Co Ltd Announces Discontinuation Of Phase 3 MARQUEE Clinical Trial In Non-Small Cell Lung Cancer
Latest Key Developments in Pharmaceuticals
- AmerisourceBergen Corp Reaffirms FY 2013 EPS Gudiance-Conference Call
- Immunotec Inc Announces New CEO
- Novo Nordisk A/S Reports Positive Results from First Phase 3 Trial with Long-Acting Factor IX for Treatment of Haemophilia B
- Sanofi SA Announces Positive Results on Pivotal Study of Inhibitor in Myelofibrosis-DJ
- Share this
- Link this
- Digg this
Follow Reuters